Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Biomarker Of Breathing Control Abnormality Associated With Hypertension And Stroke
A study in the July 1 issue of the journal SLEEP identified a distinct ECG-derived spectrographic phenotype, designated as narrow-band elevated low frequency coupling (e-LFCNB), that is associated with prevalent hypertension, stroke, greater severity of sleep disordered breathing and sleep fragmentation in patients suffering from obstructive sleep apnea (OSA).
generic viagra online
New Diagnostic Method For Gout: Dual Energy Computed Tomography Instead Of Joint Aspiration
The most reliable method of diagnosing gout is to aspirate the joint in order to obtain fluid to verify the presence of monosodium urate crystals (uric acid). Up to now, computed tomography (CT) has played a limited role in the evaluation of gout, since conventional CT systems cannot reliably verify deposits of uric acid. However, a current study at the Vancouver General Hospital in Canada gives rise to speculation that dual-energy computed tomography (DECT) could radically change the diagnosis of this disease. DECT enables fast, noninvasive examinations and, based on initial evaluations, has the potential to surpass the invasive gold standard and clinical examination in terms of reliability. Investigations have confirmed the high sensitivity of the DECT method in detecting uric acid deposits. The Canadian scientists used the SOMATOM Definition computed tomography (CT scanner) from Siemens for their investigation. This system is the only CT scanner worldwide that features two X-ray tubes capable of simultaneously producing different energies.
News of the day
Anterior Cingulate Cortex: Monitoring The Outcomes Of Others' Decisions
Good decision-making helps us to achieve our goals in a complicated world. Understanding which decisions are successful and which ones fail is important, and learning how other people make decisions is an important way of refining this ability. What happens in the brain when this useful information is withheld? Brain imaging researchers from Royal Holloway University of London (UK) investigated activity in the human brain at the time that volunteers interpreted the successes and failures of their own decisions, or the successes and failures of others" decisions. Crucially, when this important information was withheld, a region of the brain called the Anterior Cingulate Cortex became active in different ways depending on whether the information withheld related to decisions of the person in the scanner, or whether it related to the person that they were monitoring during the experiment. This tells us that this area works in different ways depending on whether gaps in important information relate to ourselves, or whether they relate to others".
Public Health

First Viable Treatment Option For Highly Resistant Form Of CML May Be Provided By ChemGenex's Omacetaxine

ChemGenex Pharmaceuticals Limited (ChemGenex) (ASX:CXS) announced that the latest data from its pivotal study of omacetaxine in patients with T315I-positive chronic myeloid leukemia (CML) was the subject of an oral presentation and discussion at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. The open label Phase 2/3 study (CGX-635-CML-202) investigated the use of omacetaxine, administered subcutaneously in CML patients who had failed imatinib and who have the highly drug resistant T315I kinase domain mutation. Dr. Jorge Cortes, MD, Professor of Medicine and Deputy Chair in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center, a lead investigator in the study, presented the data. Dr. Cortes said, "It appears that omacetaxine was well tolerated in this study and durable hematological and cytogenetic responses were observed in some CML patients with the T315I mutation." He added that "Several novel drugs have already been investigated in this difficult-to-treat population, but they have not had a reasonable risk:benefit ratio. These results suggest that omacetaxine may represent the first viable treatment option for this population of patients who currently have no established treatment options." Data were presented from 66 patients: 40 in chronic phase, 16 in accelerated phase and 10 in blast phase. Highlights of the data were: * Chronic phase patients Complete hematologic response (CHR) rate of 85% with a median response duration 8.9 months Major cytogenetic response (MCyR) rate of 15% with a median response duration 6.1 months Accelerated phase patients CHR rate of 31% with a median duration 4.1 months MCyR rate of 6% with a median response duration 1.8 months Blast phase patients CHR rate of 20% with a median duration 3.3 months Tolerability Investigators reported that omacetaxine is generally well tolerated, and that the most common side effect is reversible and transient myelosuppression. Commenting on the presentation, Dr. Greg Collier, Chief Executive Officer and Managing Director of ChemGenex, said, "This is a very important milestone in the development of omacetaxine and in the evolution of ChemGenex. The data presented today will be provided to the FDA in the final part of our rolling NDA submission; this project remains on target for completion in Q3 this year." Dr. Collier finished by expressing his deep appreciation for patients and investigators who participated in this important trial. Dr. Collier and ChemGenex"s Chief Medical Officer Dr. Adam Craig will host an investor conference call and webcast to discuss the clinical results from both ASCO and the EHA Congress on Thursday 11th of June at 10 am AEST. Omacetaxine Overview Omacetaxine mepesuccinate is a first-in-class cetaxine with demonstrated clinical activity as a single agent in a range of hematological malignancies. Omacetaxine has a novel mechanism of action, specifically binding to the ribosomal A-site cleft and inhibiting protein translation of short-lived oncoproteins that are upregulated in leukemic cells (particularly Cyclin-D1, Mcl-1 and c-Myc). As omacetaxine acts independently of tyrosine kinase inhibitors, it may have a therapeutic advantage for patients who have developed resistance to TKIs. Omacetaxine is administered subcutaneously. Joan Kureczka Kureczka/Martin Associates


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009